Scinai Immunotherapeutics Ltd ADR (SCNI)

$1.66 -0.01 (-0.60%)
Market Cap 1.17M
Revenue (ttm) 1.31M
Net Income (ttm) -8.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -634.35%
Debt to Equity Ratio 0.02
Volume 3,493,600
Avg Vol 176,364
Day's Range N/A - N/A
Shares Out 707,000.00
Stochastic %K 5%
Beta 2.08
Analysts Strong Buy
Price Target $8.00

Company Profile

Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturi...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 8 930 2529
Fax: 972 8 930 2531
Address:
Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus, Jerusalem, Israel
Aburose
Aburose Sep. 14 at 3:08 AM
$SCNI needs to go over 3 if it wants to go
1 · Reply
sailor7
sailor7 Sep. 14 at 2:53 AM
$CRBP $NCT.X $SCNI $SOAR $VSME VSME cost to borrow 410% , let’s get a nice big green momentum tomorrow
0 · Reply
AlertsAndNews
AlertsAndNews Sep. 14 at 2:39 AM
Updated gappers here from Friday. $NCT.X $CRBP $VSME $SCNI $SOAR Lets have a great week!
0 · Reply
Aburose
Aburose Sep. 14 at 2:15 AM
$SCNI over 3 to go
0 · Reply
Modo6177
Modo6177 Sep. 14 at 2:11 AM
$SCNI should I trust anything run by an Epstein?
0 · Reply
Aburose
Aburose Sep. 14 at 1:28 AM
$SCNI over 3 wild
1 · Reply
Bullbear1010101
Bullbear1010101 Sep. 14 at 12:27 AM
$SCNI who scared and sold 1.75!
0 · Reply
Aburose
Aburose Sep. 14 at 12:22 AM
$SCNI 5+
1 · Reply
Aburose
Aburose Sep. 14 at 12:21 AM
$SCNI A Jewish pharmaceutical company could see a strong rise.
0 · Reply
Aburose
Aburose Sep. 14 at 12:18 AM
$SCNI breaking 3 wild
0 · Reply
Latest News on SCNI
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business

Tue, 08 Sep 2026 09:18:00 -0400 - 5 days ago

Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business

Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum

Mon, 24 Aug 2026 07:00:00 -0400 - 20 days ago

Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum

Scinai Immunotherapeutics Ltd – ADR trading halted, news pending

2026-08-20T23:55:11.000Z - 24 days ago

Scinai Immunotherapeutics Ltd – ADR trading halted, news pending

Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration

Mon, 10 Aug 2026 06:34:00 -0400 - 4 weeks ago

Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration

Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives

Wed, 10 Jun 2026 07:55:00 -0400 - 3 months ago

Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives

Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility

Wed, 20 May 2026 07:00:00 -0400 - 3 months ago

Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility

Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe

Fri, 15 May 2026 08:05:00 -0400 - 4 months ago

Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe

Why Is Scinai Immunotherapeutics Stock (SCNI) Up Today?

2026-04-25T00:50:00.000Z - 4 months ago

Why Is Scinai Immunotherapeutics Stock (SCNI) Up Today?

Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today

Fri, 24 Apr 2026 10:25:04 -0400 - 4 months ago

Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today

Scinai Immunotherapeutics announces $2.61M private placement

2026-04-24T12:16:55.000Z - 4 months ago

Scinai Immunotherapeutics announces $2.61M private placement

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

Fri, 24 Apr 2026 08:00:00 -0400 - 4 months ago

Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing

Scinai Immunotherapeutics completes strategic reorganization

2026-04-06T11:17:23.000Z - 5 months ago

Scinai Immunotherapeutics completes strategic reorganization

Scinai Immunotherapeutics targets $5M in CDMO revenue in 2026

2026-04-06T11:10:47.000Z - 5 months ago

Scinai Immunotherapeutics targets $5M in CDMO revenue in 2026

Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

Mon, 06 Apr 2026 07:00:00 -0400 - 5 months ago

Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

Wed, 01 Apr 2026 07:35:00 -0400 - 5 months ago

Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

Scinai Immunotherapeutics highlights expanded CDMO platform

2026-03-19T12:08:05.000Z - 5 months ago

Scinai Immunotherapeutics highlights expanded CDMO platform

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

Mar 19, 2026, 7:50 AM EDT - 5 months ago

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

Mar 16, 2026, 4:05 PM EDT - 6 months ago

Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price

Scinai Immunotherapeutics signs second amendment to PinCell option agreement

2026-03-02T14:30:59.000Z - 6 months ago

Scinai Immunotherapeutics signs second amendment to PinCell option agreement

Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

Mar 2, 2026, 9:20 AM EST - 6 months ago

Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform

Feb 25, 2026, 8:11 AM EST - 6 months ago

Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform

Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm

Feb 17, 2026, 7:00 AM EST - 6 months ago

Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm

Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL

Jan 7, 2026, 7:00 AM EST - 8 months ago

Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL

Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances

Dec 2, 2025, 8:50 AM EST - 9 months ago

Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances

Scinai Immunotherapeutics awarded grant from Israel Innovation Authority

2025-10-06T11:40:52.000Z - 11 months ago

Scinai Immunotherapeutics awarded grant from Israel Innovation Authority

Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities

Oct 6, 2025, 7:30 AM EDT - 11 months ago

Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities

Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

Sep 2, 2025, 7:30 AM EDT - 1 year ago

Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

Scinai Immunotherapeutics’ PC111 featured in peer-reviewed publication

2025-07-29T11:31:12.000Z - 1 year ago

Scinai Immunotherapeutics’ PC111 featured in peer-reviewed publication

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

Jul 29, 2025, 7:15 AM EDT - 1 year ago

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

Jun 5, 2025, 9:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

May 30, 2025, 7:00 AM EDT - 1 year ago

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

Scinai Announces Annual Financial Results for 2024

May 7, 2025, 4:01 PM EDT - 1 year ago

Scinai Announces Annual Financial Results for 2024

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

May 1, 2025, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Mar 27, 2025, 9:25 AM EDT - 1 year ago

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

Scinai Immunotherapeutics announces $10M standby equity purchase agreement

2025-03-05T12:37:36.000Z - 1 year ago

Scinai Immunotherapeutics announces $10M standby equity purchase agreement

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Mar 5, 2025, 7:30 AM EST - 1 year ago

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Scinai Immunotherapeutics files to sell 3.02M ADS for holders

2025-03-04T22:30:58.000Z - 1 year ago

Scinai Immunotherapeutics files to sell 3.02M ADS for holders

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Jan 6, 2025, 7:31 AM EST - 1 year ago

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Dec 16, 2024, 9:25 AM EST - 1 year ago

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Dec 5, 2024, 8:25 AM EST - 1 year ago

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

Nov 27, 2024, 8:00 AM EST - 1 year ago

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Nov 22, 2024, 7:15 AM EST - 1 year ago

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

Oct 31, 2024, 6:59 AM EDT - 1 year ago

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

Sep 9, 2024, 11:12 AM EDT - 2 years ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics regains compliance with Nasdaq

2024-08-29T10:35:55.000Z - 2 years ago

Scinai Immunotherapeutics regains compliance with Nasdaq

Scinai Regains Full Compliance with Nasdaq Listing Requirements

Aug 29, 2024, 6:31 AM EDT - 2 years ago

Scinai Regains Full Compliance with Nasdaq Listing Requirements

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Aug 21, 2024, 8:45 AM EDT - 2 years ago

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Aug 20, 2024, 9:30 AM EDT - 2 years ago

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Aug 15, 2024, 7:00 AM EDT - 2 years ago

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

Scinai Immunotherapeutics’ IL-17 nanoAb receives positive regulatory feedback

2024-07-23T11:13:35.000Z - 2 years ago

Scinai Immunotherapeutics’ IL-17 nanoAb receives positive regulatory feedback

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Jul 23, 2024, 7:00 AM EDT - 2 years ago

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results

Jul 15, 2024, 12:31 PM EDT - 2 years ago

Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results

Scinai Immunotherapeutics’ psoriasis candidate shows efficacy in study

2024-07-15T11:10:01.000Z - 2 years ago

Scinai Immunotherapeutics’ psoriasis candidate shows efficacy in study

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

Jul 15, 2024, 7:00 AM EDT - 2 years ago

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

Jul 8, 2024, 8:14 AM EDT - 2 years ago

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Jul 3, 2024, 9:32 AM EDT - 2 years ago

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Scinai Publishes Q1 2024 Financial Results and Provides Business Update

Jul 2, 2024, 8:12 AM EDT - 2 years ago

Scinai Publishes Q1 2024 Financial Results and Provides Business Update

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

Jun 13, 2024, 7:00 AM EDT - 2 years ago

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement

Jun 7, 2024, 7:00 AM EDT - 2 years ago

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement

Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance

May 24, 2024, 4:01 PM EDT - 2 years ago

Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update

May 15, 2024, 4:01 PM EDT - 2 years ago

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update

Aburose
Aburose Sep. 14 at 3:08 AM
$SCNI needs to go over 3 if it wants to go
1 · Reply
sailor7
sailor7 Sep. 14 at 2:53 AM
$CRBP $NCT.X $SCNI $SOAR $VSME VSME cost to borrow 410% , let’s get a nice big green momentum tomorrow
0 · Reply
AlertsAndNews
AlertsAndNews Sep. 14 at 2:39 AM
Updated gappers here from Friday. $NCT.X $CRBP $VSME $SCNI $SOAR Lets have a great week!
0 · Reply
Aburose
Aburose Sep. 14 at 2:15 AM
$SCNI over 3 to go
0 · Reply
Modo6177
Modo6177 Sep. 14 at 2:11 AM
$SCNI should I trust anything run by an Epstein?
0 · Reply
Aburose
Aburose Sep. 14 at 1:28 AM
$SCNI over 3 wild
1 · Reply
Bullbear1010101
Bullbear1010101 Sep. 14 at 12:27 AM
$SCNI who scared and sold 1.75!
0 · Reply
Aburose
Aburose Sep. 14 at 12:22 AM
$SCNI 5+
1 · Reply
Aburose
Aburose Sep. 14 at 12:21 AM
$SCNI A Jewish pharmaceutical company could see a strong rise.
0 · Reply
Aburose
Aburose Sep. 14 at 12:18 AM
$SCNI breaking 3 wild
0 · Reply
Aburose
Aburose Sep. 14 at 12:15 AM
$SCNI great news for the company
0 · Reply
Aburose
Aburose Sep. 14 at 12:12 AM
$SCNI 12 coming
0 · Reply
topstockalerts
topstockalerts Sep. 13 at 6:35 PM
After Hours Top Gainers $NCT.X $CRBP $SCNI $VSME $MLEC
0 · Reply
Decaprio
Decaprio Sep. 13 at 5:15 PM
$SCNI Caprio Trades is moving to the next stage. Premium Discord access is now subscription-based. 🔒 Members get access to: 📊 Daily alerts & setups 📈 Technical analysis 🔥 Top gainers & momentum stocks 🎓 Education & Trading Clinic 📄 Nasdaq filings & catalysts 📊 Performance tracking Last week, every alert reached our planned entry and hit at least one target. 🎯 We focus on one thing: clear levels, defined risk, and no chasing. 💳 Join here: https://buy.stripe.com/8x26oGabi9lt8WGaD6aR20E ⚠️ Use your correct email during payment so we can match your subscription with your Discord account. 🐺 CAPRIO TRADES Clear Levels. Defined Risk. No Chasing. #Stocks #Trading #DayTrading #StockMarket #Premarket #MomentumTrading #MicroCaps
0 · Reply
MingChoo
MingChoo Sep. 13 at 4:13 PM
$SCNI Top watch10
0 · Reply
Ric_1M
Ric_1M Sep. 13 at 12:49 PM
$NCT $CRBP $SCNI $VSME $MLEC "When you want something, all the universe conspires in helping you to achieve it." Paulo Coelho
1 · Reply
ValuePrince
ValuePrince Sep. 13 at 6:40 AM
$SCNI 🌌
0 · Reply
Richard_Roma
Richard_Roma Sep. 12 at 7:07 AM
$SCNI hoping to dump this trash onto others with p&d
0 · Reply
topstockalerts
topstockalerts Sep. 12 at 1:10 AM
After Hours Top Gainers $NCT.X $CRBP $SCNI $VSME $MLEC
1 · Reply
et1000
et1000 Sep. 11 at 11:52 PM
Ticker MLEC is the next nano float runner ! Every small float ticker has been running almost 500% recently Would not be surprised if they send MLEC up next. MLEC starting to make its move now! Only 573k shares outstanding! 💎 $NCT.X $CRBP $SCNI $VSME flying
0 · Reply
AlertsAndNews
AlertsAndNews Sep. 11 at 11:26 PM
Happy Friday. Gappers in after hours trading $NCT.X $CRBP $VSME $SOAR $SCNI I'll update at some point this weekend. Cheers.
0 · Reply